Treatment of Burkitt lymphoma in children and adults: Lessons from Africa

Current Hematologic Malignancy Reports

Volumn 1, Issue 4, 2006, Pages 230-240

  Magrath, Ian T ^a  

^a INTERNATIONAL NETWORK FOR CANCER TREATMENT AND RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIBIOTIC AGENT; CARMUSTINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MELPHALAN; METHOTREXATE; PREDNISONE; RITUXIMAB; TIOGUANINE; VINCRISTINE;

AFRICA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LEUKEMIA; BONE MARROW SUPPRESSION; BURKITT LYMPHOMA; CANCER SURVIVAL; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG TOLERANCE; HIGH RISK POPULATION; HUMAN; JAW TUMOR; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; RECURRENT CANCER; REMISSION;

ADULT; AGE FACTORS; ANTHRACYCLINES; ANTIBODIES, MONOCLONAL; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BURKITT LYMPHOMA; CENTRAL NERVOUS SYSTEM; CHILD; DIAGNOSIS, DIFFERENTIAL; DRUG THERAPY; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; METHOTREXATE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SALVAGE THERAPY; TREATMENT OUTCOME; UGANDA;

EID: 33846186459     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-006-0004-9     Document Type: Article

References (79)

1. Burkitt D: A sarcoma involving the jaws in African children. Brit J Surg 1958, 46:218-223.
2. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 1982, 49:2112-2135.
3. Coiffier B, Gisselbrecht C, Vose JM, et al.: Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. J Clin Oncol 1991, 9:211-219.
4. Miller TP, Grogan TM, Dahlberg S, et al.: Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial. Blood 1994, 83:1460-1466.
5. Magrath IT, Ziegler JL: Bone marrow involvement in Burkitt's lymphoma and its relationship to acute B-cell leukemia. Leukemia Res 1980, 4:33-59.
6. Hoelzer D, Ludwig W-D, Thiel E, et al.: Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood 1996, 87:495-508.
7. Blum K, Lozanski G, Byrd JC: Adult Burkitt leukemia and lymphoma. Blood 2004, 104:3009-3020. Excellent review of pathogenesis and treatment.
8. Anderson JR, Wilson JF, Jenkin DT, et al.: Childhood non-Hodgkin's lymphoma. The results of a randomized therapeutic trial comparing a 4-drug regimen (COMP) with a 10-drug regimen (LSA2-L2). N Engl J Med 1983, 308:559-565.
9. Anderson JR, Jenkin RD, Wilson JF, et al.: Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin's lymphoma: a report of CCG-551 from the Children's Cancer Group. J Clin Oncol 1993, 11:1024-1032.
10. Magrath I, Adde M, Shad A, et al.: Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 1996, 14:925-934.
11. Adde M, Shad A, Venzon D, et al.: Additional chemotherapy agents improve treatment outcome for children and adults with advanced B-cell lymphomas. Semin Oncol 1998, 25(2 Suppl 4):33-39.
12. Reiter A, Schrappe M, Tiemann M, et al.: Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. Blood 1999, 94:3294-3306.
13. Patte C, Auperin A, Michon J, et al.; on behalf of the Société Française d'Oncologie Pédiatrique: The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 2001, 97:3370-3379.
14. Spreafico F, Massimino M, Luksch R, et al.: Intensive, very short-term chemotherapy for advanced Burkitt's lymphoma in children. J Clin Oncol 2002, 20:2783-2788.
15. Thomas DA, Cortes J, O'Brien S, et al.: Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol 1999, 17:2461-2470.
16. Lee EJ, Petroni GR, Schiffer CA, et al.: Brief-duration high-intensity chemotherapy for patients with small noncleaved cell lymphoma or FAB L3 acute lymphocytic leukemia: results of Cancer and Leukemia Group B Study 9251. J Clin Oncol 2001, 19:4014-4022.
17. Sweetenham JW, Pearce R, Taghipour G, et al.: Adult Burkitt's and Burkitt-like non-Hodgkin's lymphoma-outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from the European Group for Blood and Marrow Transplantation. J Clin Oncol 1996, 14:2465-2472.
18. Mead GM, Sydes MR, Walewski J, et al.; on behalf of the UKLG LY06 collaborators: An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol 2002, 13:1264-1274.
19. Lacasce A, Howard O, Lib S, et al.: Modified Magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity. Leuk Lymphoma 2004, 45:761-767. Results in adults with a higher median age (47), using a protocol described in references 10 and 11.
20. Soussain C, Patte C, Ostronoff M, et al.: Small noncleaved cell lymphoma and leukemia in adults. A retrospective study of 65 adults treated with the LMB pediatric protocols. Blood 1995, 85:664-674.
21. Pees HW, Radtke H, Schwamborn J, Graf N: The BFM-protocol for HIV-negative Burkitt's lymphomas and L3 ALL in adult patients: a high chance for cure. Ann Hematol 1992, 65:201-205.
22. Wang ES, Straus DJ, Teruya-Feldstein J, et al.: Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. Cancer 2003, 98:1196-1205. Tolerance of a high-intensity protocol in patients with HIV-associated Burkitt lymphoma.
23. Magrath IT: African Burkitt's lymphoma. History, biology, clinical features, and treatment. Am J Pediatr Hematol Oncol 1991, 13:222-246.
24. Karajannis MA, Hummel M, Oschlies I, et al.: Epstein-Barr virus infection in Western European pediatric non-Hodgkin lymphomas [letter]. Blood 2003, 102:4244.
25. Burkitt D: Long term remissions following one and two dose chemotherapy for African lymphoma. Cancer 1967, 20:756.
26. Magrath I, Lee YJ, Anderson T, et al.: Prognostic factors in Burkitt's lymphoma: importance of total tumor burden. Cancer 1980, 45:1507-1515.
27. Morrow RH, Pike MC, Kisuule A: Survival of Burkitt's lymphoma patients in Mulago Hospital, Uganda. Br Med J 1967, 4:323-327.
28. Fialkow PJ: Glucose-6-phosphate dehydrogenase (G-6-PD) markers in Burkitt lymphoma and other malignancies. Haematol Blood Transfus 1977, 20:297-305.
29. Barriga F, Whang-Peng J, Lee E, et al.: Development of a second clonally discrete Burkitt's lymphoma in a human immunodeficiency virus-positive homosexual patient. Blood 1988, 72:792-795.
30. Ngu VA: Chemotherapy of Burkitt's tumor at the University of Ibadan, Nigeria. JAMA 1972, 222:1166.
31. Clifford P: Long term survival of patients with Burkitt's lymphoma. An assessment of treatment and other factors which may relate to survival. Cancer Res 1967, 27:2578.
32. Ziegler JL, Morrow RH Jr, Fass L, et al.: Treatment of Burkitt's tumor with cyclophosphamide. Cancer 1970, 26:474-484.
33. Ziegler JL, Bluming AZ, Magrath IT, Carbone PP: Intensive chemotherapy in patients with generalized Burkitt's lymphoma. Int J Cancer 1972, 10:254-261.
34. Ziegler JL, Bluming AZ: Intrathecal chemotherapy in Burkitt's lymphoma. Br Med J 1971, 3:508-512.
35. Haddy TB, Adde MA, Magrath IT: CNS involvement in small noncleaved-cell lymphoma: is CNS disease per se a poor prognostic sign? J Clin Oncol 1991, 9:1973-1982.
36. Olweny CL, Atine I, Kaddu-Mukasa A, et al.: Cerebrospinal irradiation of Burkitt's lymphoma. Failure in preventing central nervous system relapse. Acta Radiol Ther Phys Biol 1977, 16:225-231.
37. Olweny CL, Katongole-Mbidde E, Kaddu-Mukasa A, et al.: Treatment of Burkitt's lymphoma: randomized clinical trial of single-agent versus combination chemotherapy. Int J Cancer 1976, 17:436-440.
38. Olweny CL, Katongole-Mbidde E, Otim D, et al.: Long-term experience with Burkitt's lymphoma in Uganda. Int J Cancer 1980, 26:261-266.
39. Arseneau JC, Canellos GP, Banks PM, et al.: American Burkitt's lymphoma: a clinicopathologic study of 30 cases. I. Clinical factors relating to prolonged survival. Am J Med 1975, 58:314-321.
40. Ziegler JL: Treatment results of 54 American patients with Burkitt's lymphoma are similar to the African experience. N Engl J Med 1977, 297:75-80.
41. Appelbaum FR, Deisseroth AB, Graw RG Jr, et al.: Prolonged complete remission following high dose chemotherapy of Burkitt's lymphoma in relapse. Cancer 1978, 41:1059-1063.
42. Di Nicola M, Carlo-Stella C, Mariotti J, et al.: High response rate and manageable toxicity with an intensive, short-term chemotherapy programme for Burkitt's lymphoma in adults. Brit J Haematol 2004, 126:815-820.
43. van Imhoff GW, van der Holt B, MacKenzie MA, et al.: Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON): Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma. Leukemia 2005, 19:945-952.
44. Rizzieri DA, Johnson JL, Niedzwiecki D, et al.: Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251. Cancer 2004, 100:1438-1448.
45. Djerassi I, Kim JS: Methotrexate and citrovorum factor rescue in the management of childhood lymphosarcoma and reticulum cell sarcoma (non-Hodgkin's lymphomas): prolonged unmaintained remissions. Cancer 1976, 38:1043-1051.
46. Magrath IT, Janus C, Edwards BK, et al.: An effective therapy for both undifferentiated (including Burkitt's) lymphomas and lymphoblastic lymphomas in children and young adults. Blood 1984, 63:1102-1111.
47. Murphy SB, Bowman WP, Abromowitch M, et al.: Results of treatment of advanced-stage Burkitt's lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine. J Clin Oncol 1986, 4:1732-1739.
48. Gadner H, Muller-Weihrich S, Riehm H: [Treatment strategies in malignant non-Hodgkin lymphomas in childhood] [German]. Onkologie 1986, 9:126-130.
49. Schwenn MR, Blattner SR, Lynch E, Weinstein HJ: HiC-COM: a 2-month intensive chemotherapy regimen for children with stage III and IV Burkitt's lymphoma and B-cell acute lymphoblastic leukemia. J Clin Oncol 1991, 9:133-138.
50. Woessmann W, Seidemann K, Mann G, et al.: BFM Group: The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood 2005, 105:948-958. Speaks to the importance of methotrexate in children with Burkitt lymphoma.
51. Ferreri AJ, Guerra E, Regazzi M: Area under the curve of methotrexate and creatinine clearance are outcome-deter-mining factors in primary CNS lymphomas. Br J Cancer 2004, 90:353-358. Speaks to the importance and tolerance of high-dose methotrexate in adults with primary central nervous system lymphomas.
52. Divine M, Lepage E, Briere J, et al.: Is the small non-cleaved-cell lymphoma histologic subtype a poor prognostic factor in adult patients? A case-controlled analysis. The Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1996, 14:240-248.
53. Jost LM, Jacky E, Dommann-Scherrer C, et al.: Short-term weekly chemotherapy followed by high-dose therapy with autologous bone marrow transplantation for lymphoblastic and Burkitt's lymphomas in adult patients. Ann Oncol 1995, 6:445-451.
54. Sposto R, Meadows AT, Chilcote RR, et al.: Comparison of long-term outcome of children and adolescents with disseminated non-lymphoblastic non-Hodgkin lymphoma treated with COMP or daunomycin-COMP: a report from the Children's Cancer Group. Med Pediatr Oncol 2001, 37:432-441.
55. Patte C, Bernard A, Hartmann O, et al.: High-dose methotrexate and continuous infusion Ara-C in children's non-Hodgkin's lymphoma: phase II studies and their use in further protocols. Pediatr Hematol Oncol 1986, 3:11-18.
56. Gentet JC, Patte C, Quintana E: Phase II study of cytarabine and etoposide in children with refractory or relapsed non-Hodgkin's lymphoma: a study of the French Society of Pediatric Oncology. J Clin Oncol 1990, 8:661-665.
57. Magrath I, Adde M, Sandlund J, Jain V: Ifosfamide in the treatment of high-grade recurrent non-Hodgkin's lymphomas. Hematol Oncol 1991, 9:267-274.
58. Todeschini G, Tecchio C, Degani D, et al.: Eighty-one percent event-free survival in advanced Burkitt's lymphoma/leukemia: no differences in outcome between pediatric and adult patients treated with the same intensive pediatric protocol. Ann Oncol 1997, 8(Suppl 1):77-81.
59. Magrath I: The non-Hodgkin's lymphomas in children. In Oxford Textbook of Oncology. Edited by Peckham MJ, Veronesi U, Pinedo HM. Oxford: Oxford Medical Publications; 1995:1809-1851.
60. Sparano JA, Negassa A, Lansigan E, et al.: Phase I trial of infusional cyclophosphamide, doxorubicin, and etoposide plus granulocyte-macrophage colony stimulating factor (GM-CSF) in non-Hodgkin's lymphoma. Med Oncol 2005, 22:257-268. Speaks to role of colony-stimulating factors in increasing dose density.
61. Todeschini G, Gelio S, Tecchio C: Rituximab-CHOP or two-weekly CHOP + G-CSF in aggressive lymphoma of the elderly? Ann Oncol 2004, 15:538-539.
62. Haralambieva E, Boerma EJ, van Imhoff GW, et al.: Clinical, immunophenotypic, and genetic analysis of adult lymphomas with morphologic features of Burkitt lymphoma. Am J Surg Pathol 2005, 29:1086-1094. Addresses the issue of lymphomas intermediate in morphology between Burkitt lymphoma and diffuse large-B-cell lymphomas (DLBCLs).
63. Hummel M, Bentink S, Berger H, et al.: A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 2006, 354:2419-2430. Provides new information on the molecular profile of BL, BLL, and DLBCL.
64. Dave SS, Fu K, Wright GW, et al.; for the Lymphoma/Leukemia Molecular Profiling Project: Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 2006, 354:2431-2442. Provides new information on the molecular profiling of BL, BLL, and DLBCL.
65. Harris N, Jaffe E, Stein H, et al.: A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994, 84:1361-1392.
66. Jaffe ES, Harris NL, Stein H, Vardiman JW (eds): World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.
67. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997, 89:3909-3918.
68. Harris NL, Jaffe ES, Diebold J, et al.: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999, 17:3835-3849.
69. Braziel RM, Arber DA, Slovak ML: The Burkitt-like lymphomas: a Southwest Oncology Group study delineating phenotypic, genotypic, and clinical features. Blood 2001, 97:3713-3720.
70. Voorhees PM, Carder KA, Smith SV, et al.: Follicular lymphoma with a Burkitt translocation-predictor of an aggressive clinical course: a case report and review of the literature. Arch Pathol Lab Med 2004, 128:210-213.
71. Knezevich S, Ludkovski O, Salski C, et al.: Concurrent translocation of BCL2 and MYC with a single immunoglobulin locus in high-grade B-cell lymphomas. Leukemia 2005, 19:659-663.
72. Alizadeh AA, Eisen MB, Davis RE, et al.: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511.
73. Rosenwald A, Wright G, Chan WC, et al.: Lymphoma/Leukemia Molecular Profiling Project: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:1937-1947.
74. Oschlies I, Klapper W, Zimmermann M, et al.: Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Munster) Multicenter Trial. Blood 2006, 107:4047-4052. Demonstration of germinal-center cell origin of childhood DLBCL.
75. Dave BJ, Weisenburger DD, Higgins CM, et al.: Cytogenetics and fluorescence in situ hybridization studies of diffuse large B-cell lymphoma in children and young adults. Cancer Genet Cytogenet 2004, 153:115-121.
76. Jahnke K, Korfel A, Martus P, et al.; on behalf of the German Primary Central Nervous System Lymphoma Study Group (G-PCNSL-SG): High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma. Ann Oncol 2005, 16:445-449. Speaks to tolerance of high-dose methotrexate in elderly patients.
77. Weiser MA, O'Brien S, Thomas DA, et al.: Comparison of two different schedules of granulocyte-colony-stimulating factor during treatment for acute lymphocytic leukemia with a hyper-CVAD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) regimen. Cancer 2002, 94:285-291.
78. Divine M, Casassus P, Koscielny S, et al.; GELA; GOELAMS: Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol. Ann Oncol 2005, 16:1928-1935. Provides information on the response of adults with BL to the LMB protocol designed for children and demonstrates the value of a risk-adapted approach.
79. Thomas DA, Faderl S, O'Brien S, et al.: Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 2006, 106:1569-1580. Provides information regarding the value of rituximab in the context of a high-intensity protocol for BL in adults.